Bortezomib blocks Bax degradation in malignant B cells during treatment with TRAIL.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Blood

• Publication date

  2008-03-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1182/BLOOD-2007-08-110445PMID 18160669
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Proteasome inhibitIon specifically sensitizes leukemic cells to anthracyclin-induced apoptosis through the accumulation of Bim and Bax pro-apoptotic proteins

  2007cited by this paper
• The N-terminal conformation of Bax regulates cell commitment to apoptosis

  2007cited by this paper
• Apoptosis Initiated When BH3 Ligands Engage Multiple Bcl-2 Homologs, Not Bax or Bak

  2007cited by this paper
• The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.

  2007cited by this paper
• Histone Deacetylase Inhibitor Depsipeptide (FK228) Induces Apoptosis in Leukemic Cells by Facilitating Mitochondrial Translocation of Bax, Which Is Enhanced by the Proteasome Inhibitor Bortezomib

  2006cited by this paper
• The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status.

  2006cited by this paper
• Mcl-1 Interacts with Truncated Bid and Inhibits Its Induction of Cytochrome c Release and Its Role in Receptor-mediated Apoptosis*

  2006cited by this paper
• Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity.

  2006cited by this paper
• Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.

  2006cited by this paper
• Trichostatin A sensitizes TRAIL-resistant myeloma cells by downregulation of the antiapoptotic Bcl-2 proteins

  2006cited by this paper
• Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic

  2006cited by this paper
• Gallium-induced cell death in lymphoma: role of transferrin receptor cycling, involvement of Bax and the mitochondria, and effects of proteasome inhibition

  2006cited by this paper
• Loss of proapoptotic Bcl-2-related multidomain proteins in primary melanomas is associated with poor prognosis.

  2006cited by this paper
• Additive cytotoxic effect of bortezomib in combination with anti-CD20 or anti-CD52 monoclonal antibodies on chronic lymphocytic leukemia cells.

  2006cited by this paper
• The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells

  2006cited by this paper
• The Proteasome Inhibitor Bortezomib (Velcade) Sensitizes Some Human Tumor Cells to Apo2L/TRAIL‐Mediated Apoptosis

  2005cited by this paper
• Type I and type II reactions in TRAIL-induced apoptosis – results from dose–response studies

  2005cited by this paper
• In vitro cytotoxic effect of proteasome inhibitor bortezomib in combination with purine nucleoside analogues on chronic lymphocytic leukaemia cells

  2005cited by this paper
• The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim

  2005cited by this paper
• Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells.

  2005cited by this paper
• Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells.

  2005cited by this paper
• Regulation of the Proapoptotic ARTS Protein by Ubiquitin-mediated Degradation*

  2005cited by this paper
• Bcl-2 Inhibitors Sensitize Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis by Uncoupling of Mitochondrial Respiration in Human Leukemic CEM Cells

  2004cited by this paper
• Treatment of human chronic lymphocytic leukemia cells with the proteasome inhibitor bortezomib promotes apoptosis.

  2004cited by this paper
• Mcl‐1 and Bcl‐2/Bax ratio are associated with treatment response but not with Rai stage in B‐cell chronic lymphocytic leukemia

  2004cited by this paper
• Pharmacology, pharmacokinetics, and practical applications of bortezomib.

  2004cited by this paper
• Increase in the ratio of mitochondrial Bax/Bcl-XL induces Bax activation in human leukemic K562 cell line

  2004cited by this paper
• Differential Apoptotic Response to the Proteasome Inhibitor Bortezomib (VELCADETM, PS-341) in Bax-Deficient and p21-Deficient Colon Cancer Cells

  2003cited by this paper
• The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP.

  2003cited by this paper
• The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells

  2003cited by this paper
• Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.

  2003cited by this paper
• Conformational change and mitochondrial translocation of Bax accompany proteasome inhibitor-induced apoptosis of chronic lymphocytic leukemic cells

  2003cited by this paper
• Bax conformational change is a crucial step for PUMA-mediated apoptosis in human leukemia.

  2003cited by this paper
• Potential mechanisms of leukemia cell resistance to TRAIL-induced apopotosis

  2003cited by this paper
• NF-κB as a Therapeutic Target in Multiple Myeloma*

  2002cited by this paper
• Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemia

  2002cited by this paper
• NF-kappa B as a therapeutic target in multiple myeloma.

  2002cited by this paper
• Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia

  2002cited by this paper
• Bax translocation is crucial for the sensitivity of leukaemic cells to etoposide-induced apoptosis

  2001cited by this paper
• TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications.

  2001cited by this paper
• Trail-induced apoptosis in Type I leukemic cells is not enhanced by overexpression of bax.

  2001cited by this paper
• 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer

  2001cited by this paper
• Proteasomes: The World of Regulatory Proteolysis

  2000cited by this paper
• Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression.

  2000cited by this paper
• Ubiquitin-mediated Degradation of the Proapoptotic Active Form of Bid

  2000cited by this paper
• Subcellular distribution and redistribution of Bcl-2 family proteins in human leukemia cells undergoing apoptosis.

  1999cited by this paper
• Regulation of the apoptotic response to radiation damage in B cell development

  1998cited by this paper
• mdm2 and bax, downstream mediators of the p53 response, are degraded by the ubiquitin-proteasome pathway.

  1998cited by this paper
• Bax-α promotes apoptosis induced by cancer chemotherapy and accelerates the activation of caspase 3-like cysteine proteases in p53 double mutant B lymphoma Namalwa cells

  1998cited by this paper
• Bax in Murine Thymus Is a Soluble Monomeric Protein That Displays Differential Detergent-induced Conformations*

  1998cited by this paper
• The ubiquitin–proteasome pathway: on protein death and cell life

  1998cited by this paper
• Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX.

  1996cited by this paper
• Bcl‐2, Bax and p53 expression in B‐CLL in relation to in vitro survival and clinical progression

  1996cited by this paper
• Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio.

  1996cited by this paper
• Overexpression of the Bcl-2 Protein Increases the Half-life of p21Bax(*)

  1995cited by this paper
• A new non-Hodgkin's B-cell line (DoHH2) with a chromosomal translocation t(14;18)(q32;q21).

  1991cited by this paper
• Phorbol ester-induced, cell-cycle-specific, growth inhibition of human B-lymphoma cell lines.

  1990cited by this paper
• The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53.

  1990cited by this paper
• Pharmacology, pharmacokinetics, and practical applications of bortezomib.

  1964cited by this paper

• Implications of melanogenesis stimulation in B16-F10 cells on the ubiquitin-proteasome system.

  2025cites this paper
• Bortezomib overcomes TRAIL resistance in Burkitt's lymphoma by enhancing apoptosis via reactive oxygen species-mediated DR5 upregulation and MAPK pathway activation

  2025cites this paper
• Interplay between proteasome inhibitors and NF-κB pathway in leukemia and lymphoma: a comprehensive review on challenges ahead of proteasome inhibitors

  2024cites this paper
• Comprehensive review of Bcl‐2 family proteins in cancer apoptosis: Therapeutic strategies and promising updates of natural bioactive compounds and small molecules

  2024cites this paper
• The E3 ubiquitin ligase TRIM17 promotes gastric cancer survival and progression via controlling BAX stability and antagonizing apoptosis

  2023cites this paper
• Computational Techniques for Predicting Response to Therapy for Cancer

  2023cites this paper
• Ubiquitin-proteasome pathway-mediated regulation of the Bcl-2 family: effects and therapeutic approaches

  2023cites this paper
• Killing by Degradation: Regulation of Apoptosis by the Ubiquitin-Proteasome-System

  2021cites this paper
• Dysregulation of the Ubiquitin Proteasome System in Human Malignancies: A Window for Therapeutic Intervention

  2021cites this paper
• Targeting BAX ubiquitin‐binding sites reveals that BAX activation is essential for its ubiquitin‐dependent degradation

  2020influential citation
• Bortezomib induces HSV‐1 lethality in mice with neutrophil deficiency

  2019cites this paper
• Increased autocrine interleukin‐6 production is significantly associated with worse clinical outcome in patients with chronic lymphocytic leukemia

  2019cites this paper
• Dianas terapeuticas en mieloma multiple: desregulación de mirnas y trail

  2019influential citation
• Trailing TRAIL Resistance for Targeted Cancer Therapy

  2018influential citation
• Delineating Crosstalk Mechanisms of the Ubiquitin Proteasome System That Regulate Apoptosis

  2018cites this paper
• Complex formation and turnover of mitochondrial transporters and ion channels

  2017cites this paper
• Ubiquitination and the Regulation of Membrane Proteins.

  2017cites this paper
• Drugging the undruggables: exploring the ubiquitin system for drug development

  2016cites this paper
• Direct Activation of Bax Protein for Cancer Therapy

  2016cites this paper
• STAT3 and NF-κB cooperatively control in vitro spontaneous apoptosis and poor chemo-responsiveness in patients with chronic lymphocytic leukemia

  2016cites this paper
• Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma

  2016cites this paper
• Proteasome Inhibitors in the Treatment of Multiple Myeloma

  2016cites this paper
• STRATEGIES TO MODEL AND CIRCUMVENT ACQUIRED RESISTANCE TO THERAPEUTICS IN SMALL CELL LUNG CANCER

  2016cites this paper
• The role of endoplasmic reticulum stress and inflammasome activation in inflammatory disease : identifying therapeutic targets in cystic fibrosis and haematological malignancies

  2016cites this paper
• Use of class I histone deacetylase inhibitor romidepsin in combination regimens

  2016cites this paper
• Aqueous Extract of Anticancer Drug CRUEL Herbomineral Formulation Capsules Exerts Anti-proliferative Effects in Renal Cell Carcinoma Cell Lines.

  2016cites this paper
• Chemosensitization Effect of SP1017 on Multiple Myeloma

  2016cites this paper
• Redox Homeostasis and Cellular Antioxidant Systems: Crucial Players in Cancer Growth and Therapy

  2016cites this paper
• Andrographolide reversed 5-FU resistance in human colorectal cancer by elevating BAX expression.

  2016cites this paper
• Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells

  2015cites this paper
• Rituximab-induced HMGB1 release is associated with inhibition of STAT3 activity in human diffuse large B-cell lymphoma

  2015cites this paper
• Dynamin-related protein Drp1 is required for Bax translocation to mitochondria in response to irradiation-induced apoptosis

  2015cites this paper
• DRAM1 regulates apoptosis through increasing protein levels and lysosomal localization of BAX

  2015cites this paper
• Know the enemy as well as the weapons in hand: the aberrant death pathways and therapeutic agents in chronic lymphocytic leukemia.

  2015cites this paper
• Investigating the role of T-cells in chronic lymphocytic leukemia

  2015cites this paper
• The amazing ubiquitin-proteasome system: structural components and implication in aging.

  2015cites this paper
• Asparagus racemosus leaf extract inhibits growth of UOK 146 renal cell carcinoma cell line: simultaneous oncogenic PRCCTFE3 fusion transcript inhibition and apoptosis independent cell death.

  2014cites this paper
• Ubiquitination by SAG regulates macrophage survival/death and immune response during infection

  2014influential citation
• Canonical and new generation anticancer drugs also target energy metabolism

  2014cites this paper
• Reticulum-Mitochondrion Contacts Bax at Endoplasmic by Proteasome-Mediated Degradation of Human Cytomegalovirus Inhibits Apoptosis

  2014cites this paper
• The drosophila Bcl-2 family protein Debcl is targeted to the proteasome by the β-TrCP homologue slimb

  2014cites this paper
• XIAP-targeting drugs re-sensitize PIK3CA-mutated colorectal cancer cells for death receptor-induced apoptosis

  2014cites this paper
• DAPK2 is a novel modulator of TRAIL-induced apoptosis

  2014cites this paper
• Single-agent Smac-mimetic compounds induce apoptosis in B chronic lymphocytic leukaemia (B-CLL).

  2013cites this paper
• Human Cytomegalovirus Inhibits Apoptosis by Proteasome-Mediated Degradation of Bax at Endoplasmic Reticulum-Mitochondrion Contacts

  2013cites this paper
• Why bortezomib cannot go with ‘green’?

  2013cites this paper
• Precision medicines for B‐cell leukaemias and lymphomas; progress and potential pitfalls

  2013cites this paper
• Targeted therapy of the XIAP/proteasome pathway overcomes TRAIL-resistance in carcinoma by switching apoptosis signaling to a Bax/Bak-independent ‘type I' mode

  2013cites this paper
• The DeISGylase USP18 limits TRAIL-induced apoptosis through the regulation of TRAIL levels

  2013cites this paper
• Harnessing Death Receptor Signaling for Cancer Treatment

  2013cites this paper
• Bortezomib and TRAIL: a perfect match for apoptotic elimination of tumour cells?

  2013cites this paper
• Targeting Oncogene-Induced Autophagy: A New Approach in Cancer Therapy?

  2013cites this paper
• Evading apoptosis in cancer.

  2013cites this paper
• Regulation of autophagy in hematological malignancies: role of reactive oxygen species

  2012cites this paper
• Blocking Autophagy Prevents Bortezomib-Induced NF-κB Activation by Reducing I-κBα Degradation in Lymphoma Cells

  2012cites this paper
• Proteasome Inhibitors In Cancer Therapy: A Novel Approach To A Ubiquitous Problem

  2012cites this paper
• The ubiquitin/proteasome system-dependent control of mitochondrial steps in apoptosis.

  2012cites this paper
• Ubiquitin C-terminal hydrolase-L1 (UCH-L1) stabilizes NOXA and impacts on cancer chemosusceptibility

  2012cites this paper
• The effect of TRAIL on the expression of multidrug resistant genes MDR1, LRP and GST-π in drug-resistant gastric cancer cell SGC7901/VCR.

  2012cites this paper
• BaxΔ2 Is a Novel Bax Isoform Unique to Microsatellite Unstable Tumors*

  2012cites this paper
• ZGDHu-1 promotes apoptosis of chronic lymphocytic leukemia cells.

  2012cites this paper
• WITHDRAWN: Evidence for the critical roles of NF-κB p65 and specificity proteins in the apoptosis-inducing activity of proteasome inhibitors in leukemia cells.

  2012cites this paper
• A novel tumor antigen derived from enhanced degradation of bax protein in human cancers.

  2011cites this paper
• Aberrantly activated anti‐apoptotic signalling mechanisms in chronic lymphocytic leukaemia cells: clues to the identification of novel therapeutic targets

  2011cites this paper
• Novel insights into the synergistic interaction of Bortezomib and TRAIL: tBid provides the link

  2011influential citation
• Mitochondria as Therapeutic Targets for the Treatment of Malignant Disease

  2011influential citation
• Regulating mitochondrial outer membrane proteins by ubiquitination and proteasomal degradation.

  2011cites this paper
• Second-Generation Proteasome Inhibitors

  2011cites this paper
• The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo

  2010cites this paper
• Combination effects of bortezomib with gemcitabine and EMAP II in experimental pancreatic cancer.

  2010cites this paper
• Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: the therapeutic potential of Akt inhibition

  2010cites this paper
• Proapoptotic DR4 and DR5 signaling in cancer cells: toward clinical translation.

  2010cites this paper
• Bortezomib Sensitizes Human Renal Cell Carcinomas to TRAIL Apoptosis through Increased Activation of Caspase-8 in the Death-Inducing Signaling Complex

  2010cites this paper
• TRAILing death in cancer.

  2010cites this paper
• TRAIL/TRAIL‐R in hematologic malignancies

  2010cites this paper
• Defining novel targets for immunotheraphy of human cancer

  2010cites this paper
• Combination effects of bortezomib with gemcitabine and EMAP II in experimental pancreatic cancer

  2010cites this paper
• The role of apoptosis in cancer development and treatment: focusing on the development and treatment of hematologic malignancies.

  2010cites this paper
• IBRDC2, an IBR‐type E3 ubiquitin ligase, is a regulatory factor for Bax and apoptosis activation

  2010cites this paper
• Regulation of death receptor signaling by the ubiquitin system

  2010cites this paper
• Human papillomavirus type 16 E5 protein inhibits hydrogen-peroxide-induced apoptosis by stimulating ubiquitin-proteasome-mediated degradation of Bax in human cervical cancer cells.

  2010cites this paper
• Proteasome inhibition and allogeneic hematopoietic stem cell transplantation: a review.

  2009cites this paper
• Novel drugs for chronic lymphoid leukemias: mechanism of action and therapeutic activity.

  2009cites this paper
• Bortezomib Overcomes Tumor Necrosis Factor-related Apoptosis-inducing Ligand Resistance in Hepatocellular Carcinoma Cells in Part through the Inhibition of the Phosphatidylinositol 3-Kinase/Akt Pathway*

  2009cites this paper
• Combination therapy with TRAIL: Recent developments and potential pitfalls

  2009cites this paper
• Proteasome inhibitors in cancer therapy.

  2009cites this paper
• Baxbeta: a constitutively active human Bax isoform that is under tight regulatory control by the proteasomal degradation mechanism.

  2009cites this paper
• Down-regulation of vascular endothelial growth factor receptor 2 is a major molecular determinant of proteasome inhibitor-mediated antiangiogenic action in endothelial cells.

  2009cites this paper
• Interleukin-15 enhances proteasomal degradation of bid in normal lymphocytes: implications for large granular lymphocyte leukemias.

  2009cites this paper
• Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib.

  2008cites this paper
• Imatinib and the neoplastic bone microenvironment

  2008cites this paper
• Increased proteasomal degradation of Bax is a common feature of poor prognosis chronic lymphocytic leukemia.

  2008cites this paper
• The alpha-5 helix of Bax is sensitive to ubiquitin-dependent degradation.

  2008cites this paper
• Why is CLL refractory to bortezomib?

  2008cites this paper
• SAGE analysis demonstrates increased expression of TOSO contributing to Fas-mediated resistance in CLL.

  2007cites this paper